

Sreeram V Ramagopalan

List of Publications by Year
in descending order

Source: <https://exaly.com/author-pdf/4677471/publications.pdf>

Version: 2024-02-01

75
papers

4,171
citations

201674
27
h-index

114465
63
g-index

76
all docs

76
docs citations

76
times ranked

6391
citing authors

#	ARTICLE	IF	CITATIONS
1	A ChIP-seq defined genome-wide map of vitamin D receptor binding: Associations with disease and evolution. <i>Genome Research</i> , 2010, 20, 1352-1360.	5.5	737
2	Multiple sclerosis: risk factors, prodromes, and potential causal pathways. <i>Lancet Neurology</i> , The, 2010, 9, 727-739.	10.2	459
3	Expression of the Multiple Sclerosis-Associated MHC Class II Allele HLA-DRB1*1501 Is Regulated by Vitamin D. <i>PLoS Genetics</i> , 2009, 5, e1000369.	3.5	442
4	Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study. <i>BMC Medicine</i> , 2011, 9, 1.	5.5	440
5	Environmental factors and their timing in adult-onset multiple sclerosis. <i>Nature Reviews Neurology</i> , 2010, 6, 156-166.	10.1	228
6	Rare variants in the <i>CYP27B1</i> gene are associated with multiple sclerosis. <i>Annals of Neurology</i> , 2011, 70, 881-886.	5.3	204
7	Buccals are likely to be a more informative surrogate tissue than blood for epigenome-wide association studies. <i>Epigenetics</i> , 2013, 8, 445-454.	2.7	140
8	The Inheritance of Resistance Alleles in Multiple Sclerosis. <i>PLoS Genetics</i> , 2007, 3, e150.	3.5	109
9	Prodromal symptoms of multiple sclerosis in primary care. <i>Annals of Neurology</i> , 2018, 83, 1162-1173.	5.3	98
10	Association of Infectious Mononucleosis with Multiple Sclerosis. <i>Neuroepidemiology</i> , 2009, 32, 257-262.	2.3	85
11	The effect of vitamin D-related interventions on multiple sclerosis relapses: a meta-analysis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1571-1579.	3.0	84
12	Multiple sclerosis and the major histocompatibility complex. <i>Current Opinion in Neurology</i> , 2009, 22, 219-225.	3.6	77
13	Term pregnancies and the clinical characteristics of multiple sclerosis: a population based study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 793-795.	1.9	64
14	The genetics of clinical outcome in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2008, 201-202, 183-199.	2.3	49
15	Associations between selected immune-mediated diseases and tuberculosis: record-linkage studies. <i>BMC Medicine</i> , 2013, 11, 97.	5.5	49
16	Multiple sclerosis: major histocompatibility complexity and antigen presentation. <i>Genome Medicine</i> , 2009, 1, 105.	8.2	48
17	Parental transmission of HLA-DRB1*15 in multiple sclerosis. <i>Human Genetics</i> , 2008, 122, 661-663.	3.8	47
18	Real-world data and the patient perspective: the PROMise of social media?. <i>BMC Medicine</i> , 2019, 17, 11.	5.5	44

#	ARTICLE	IF	CITATIONS
19	Genes for multiple sclerosis. Lancet, The, 2008, 371, 283-285.	13.7	41
20	The senescent methylome and its relationship with cancer, ageing and germline genetic variation in humans. Genome Biology, 2015, 16, 194.	8.8	40
21	Prevalence of primary outcome changes in clinical trials registered on ClinicalTrials.gov: a cross-sectional study. F1000Research, 2014, 3, 77.	1.6	40
22	Association of smoking with risk of multiple sclerosis: a population-based study. Journal of Neurology, 2013, 260, 1778-1781.	3.6	39
23	Multiple sclerosis in Isfahan, Iran: an update. Multiple Sclerosis Journal, 2014, 20, 1145-1147.	3.0	38
24	Hospital admissions for vitamin D related conditions and subsequent immune-mediated disease: record-linkage studies. BMC Medicine, 2013, 11, 171.	5.5	31
25	Clinical associations between gout and multiple sclerosis, Parkinson's disease and motor neuron disease: record-linkage studies. BMC Neurology, 2015, 15, 16.	1.8	31
26	A genome-wide scan in forty large pedigrees with multiple sclerosis. Journal of Human Genetics, 2007, 52, 955-962.	2.3	30
27	Real-world data in the United Kingdom: opportunities and challenges. BMC Medicine, 2016, 14, 97.	5.5	30
28	Multiple sclerosis in the Iranian immigrant population of BC, Canada: prevalence and risk factors. Multiple Sclerosis Journal, 2014, 20, 1182-1188.	3.0	24
29	Using Twitter to investigate opinions about multiple sclerosis treatments: a descriptive, exploratory study. F1000Research, 2014, 3, 216.	1.6	21
30	Parent-of-origin of HLA-DRB1*1501 and age of onset of multiple sclerosis. Journal of Human Genetics, 2009, 54, 547-549.	2.3	19
31	Geography of hospital admissions for multiple sclerosis in England and comparison with the geography of hospital admissions for infectious mononucleosis: a descriptive study. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 682-687.	1.9	19
32	Methylation of class II transactivator gene promoter IV is not associated with susceptibility to Multiple Sclerosis. BMC Medical Genetics, 2008, 9, 63.	2.1	18
33	Performing studies using the UK Clinical Practice Research Datalink: to link or not to link?. European Journal of Epidemiology, 2018, 33, 601-605.	5.7	18
34	Role of the HLA System in the Association Between Multiple Sclerosis and Infectious Mononucleosis. Archives of Neurology, 2011, 68, 469.	4.5	17
35	Evidence for an Association Between Vitamin D and Multiple Sclerosis. Current Topics in Behavioral Neurosciences, 2014, 26, 105-115.	1.7	17
36	Funding source and primary outcome changes in clinical trials registered on ClinicalTrials.gov are associated with the reporting of a statistically significant primary outcome: a cross-sectional study. F1000Research, 2015, 4, 80.	1.6	17

#	ARTICLE	IF	CITATIONS
37	Unintended consequences of machine learning in medicine?. F1000Research, 2017, 6, 1707.	1.6	15
38	Funding source and primary outcome changes in clinical trials registered on ClinicalTrials.gov are associated with the reporting of a statistically significant primary outcome: a cross-sectional study. F1000Research, 2015, 4, 80.	1.6	15
39	No Effect of Birth Weight on the Risk of Multiple Sclerosis. Neuroepidemiology, 2008, 31, 181-184.	2.3	13
40	Effect of Vitamin D supplements on relapse rate and Expanded Disability Status Scale (EDSS) in multiple sclerosis (MS): A systematic review and meta-analysis. International Journal of Preventive Medicine, 2021, 12, 42.	0.4	13
41	An analysis of characteristics of post-authorisation studies registered on the ENCePP EU PAS Register. F1000Research, 2017, 6, 1447.	1.6	13
42	No effect of preterm birth on the risk of multiple sclerosis: a population based study. BMC Neurology, 2008, 8, 30.	1.8	12
43	Time to really share real-world data?. F1000Research, 2018, 7, 1054.	1.6	12
44	Congenital Abnormalities and Multiple Sclerosis. BMC Neurology, 2010, 10, 115.	1.8	11
45	A Risk Score for Predicting Multiple Sclerosis. PLoS ONE, 2016, 11, e0164992.	2.5	11
46	An analysis of characteristics of post-authorisation studies registered on the ENCePP EU PAS Register. F1000Research, 2017, 6, 1447.	1.6	11
47	The Effect of Vitamin D Supplements on Clinical and Para-Clinical Outcomes in Patients With Multiple Sclerosis: Protocol for a Systematic Review. JMIR Research Protocols, 2019, 8, e12045.	1.0	11
48	No Effect of Parental Age on Risk of Multiple Sclerosis: A Population-Based Study. Neuroepidemiology, 2010, 34, 106-109.	2.3	10
49	The promise and challenges of blood spot methylomics. Epigenetics, 2013, 8, 775-777.	2.7	10
50	A review of data sharing statements in observational studies published in the BMJ: A cross-sectional study. F1000Research, 2017, 6, 1708.	1.6	10
51	Sex ratio of infectious mononucleosis and possible relevance to multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 359-361.	3.0	9
52	Childhood cow's milk allergy and the risk of multiple sclerosis: A population based study. Journal of the Neurological Sciences, 2010, 291, 86-88.	0.6	8
53	Under-recording of hospital bleeding events in UK primary care: a linked Clinical Practice Research Datalink and Hospital Episode Statistics study. Clinical Epidemiology, 2018, Volume 10, 1155-1168.	3.0	8
54	A review of data sharing statements in observational studies published in the BMJ: A cross-sectional study. F1000Research, 2017, 6, 1708.	1.6	8

#	ARTICLE	IF	CITATIONS
55	Lack of data sharing in observational studies. BMJ: British Medical Journal, 2017, 359, j4866.	2.3	7
56	Age at menarche and risk of multiple sclerosis (MS): a systematic review and meta-analysis. BMC Neurology, 2019, 19, 286.	1.8	7
57	Regulatory genomic regions active in immune cell types explain a large proportion of the genetic risk of multiple sclerosis. Journal of Human Genetics, 2014, 59, 211-215.	2.3	6
58	Discontinuation and primary care visits in nonvalvular atrial fibrillation patients treated with apixaban or warfarin. Journal of Comparative Effectiveness Research, 2019, 8, 371-379.	1.4	6
59	Increasing cancer risk over calendar year in people with multiple sclerosis: a case-control study. Journal of Neurology, 2021, 268, 817-824.	3.6	6
60	What is Next for the Genetics of Multiple Sclerosis?. Autoimmune Diseases, 2011, 2011, 1-3.	0.6	5
61	Sleep and BMI: Do (Fitbit) bands aid?. F1000Research, 2018, 7, 511.	1.6	5
62	Validity of social media for assessing treatment patterns in oncology patients: a case study in melanoma. JAMIA Open, 2019, 2, 416-422.	2.0	5
63	Sleep and BMI: Do (Fitbit) bands aid?. F1000Research, 2018, 7, 511.	1.6	5
64	Origins of magic: review of genetic and epigenetic effects. BMJ: British Medical Journal, 2007, 335, 1299-1301.	2.3	4
65	Comparative effectiveness of trastuzumab emtansine versus lapatinib plus chemotherapy for HER2+ metastatic breast cancer. Journal of Comparative Effectiveness Research, 2021, 10, 595-602.	1.4	4
66	Parental non-inherited HLA resistance alleles do not confer protection against multiple sclerosis. Journal of Neuroimmunology, 2008, 196, 170-172.	2.3	3
67	Early life child exposure and the risk of multiple sclerosis: A population based study. Journal of the Neurological Sciences, 2011, 307, 162-163.	0.6	3
68	Concealed effects of gene-environment interactions in genome-wide association. Multiple Sclerosis and Related Disorders, 2012, 1, 39-42.	2.0	3
69	Life after COVID-19: R WE going to help?. Journal of Comparative Effectiveness Research, 2020, 9, 525-526.	1.4	3
70	Serostatus of Epstein-Barr virus in Iranian MS patients. Acta Neurologica Belgica, 2016, 116, 43-46.	1.1	2
71	Real-world data really matter. Cmaj, 2017, 189, E1293-E1293.	2.0	2
72	Variants in ST8SIA1 do not play a major role in susceptibility to multiple sclerosis in Canadian families. Journal of Neuroimmunology, 2009, 212, 142-144.	2.3	1

#	ARTICLE	IF	CITATIONS
73	Commonly used definitions in real-world studies may underestimate the prevalence of renal disease among nonvalvular atrial fibrillation patients. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 961-968.	1.4	0
74	RWE ready for reimbursement? A round up of developments in real-world evidence relating to HTA: part 3. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 1175-1176.	1.4	0
75	Suppressor Alleles in Multiple Sclerosis: Inheritance and Interactions. <i>PLoS Genetics</i> , 2005, preprint, e150.	3.5	0